Affichage 41 à 43 des 43 essais cliniques
1 | 2 | 3 | 4 | 5 |
ESSAIS CLINIQUES
    No essai
    ClinicalTrials.gov ID
Phase Coordonnateur(rice)
(EN) A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
    Krascendo 170
    NCT05789082
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
Chadi Zakaria
514-340-8222 poste 28326
(EN) A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
    eVOLVE-Lung02
    NCT05984277
     Actif en recrutement
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
Pierre Bédard
418-835-7121
(EN) A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C
    CodeBreaK 202
    NCT05920356
     Actif en recrutement
INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUEBEC - UL
Brigitte Fortin
418-656-8711 poste 2639

Marie-Ève Morneau
418-656-8711 poste 2690
1 | 2 | 3 | 4 | 5 |